Clinical Trial

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-14 -> 2026-09-29 2026-08-01
minor Completion pushed: 2026-07-13 -> 2026-09-29 2026-08-01
Trial Details
NCT Number NCT07295951
Lead Sponsor Janssen Research & Development, LLC
Conditions Acute Lymphoblastic Leukemia, Acute Leukemias, Acute Myeloid Leukemia
Enrollment 10 participants
Start Date 2025-11-18
Primary Completion 2026-09-29 (estimated)
Study Completion 2026-09-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-31